Jennifer Boggs

Atlanta

Assistant Managing Editor at BioWorld

Assistant Managing Editor at BioWorld MedTech

Featured in: Favicon

bioworld.com Favicon

jamanetwork.com Favicon

realsimple.com Favicon

acpjournals.org Favicon

healio.com Favicon

jpeds.com

Articles

Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial

1 week ago | bioworld.com | Jennifer Boggs

Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trialTheriva Biologics Inc.’s stroma-targeting oncolytic virus approach yielded positive findings in metastatic pancreatic ductal adenocarcinoma, with the top-line readout of phase IIb data showing VCN-01 (zabilugene almadenorepvec) in combination with chemotherapy bested chemotherapy alone on primary and secondary endpoints, which included overall survival. BioWorld Clinical Cancer Oncolytic Europe U.S.
Regulus’ rare kidney disease drug draws Novartis in potential $1.7B buyout

2 weeks ago | bioworld.com | Jennifer Boggs

Regulus’ rare kidney disease drug draws Novartis in potential $1.7B buyoutRegulus Therapeutics Inc. CEO Jay Hagan told investors in a January call the company had no interest in “simply out-licensing” rights to lead candidate farabursen, an oligonucleotide targeting autosomal dominant polycystic kidney disease set to start phase III testing on a path to a potential accelerated approval.
CG Oncology’s bladder cancer therapy holding its own against J&J drug

2 weeks ago | bioworld.com | Jennifer Boggs

CG Oncology’s bladder cancer therapy holding its own against J&J drugShares of CG Oncology Inc.
Synthetic Design emerges with $20M and next-gen ADC platform

3 weeks ago | bioworld.com | Jennifer Boggs

CancerSynthetic Design emerges with $20M and next-gen ADC platformSynthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders identifying a single clear goal: how to deliver more payload to a target cancer cell. BioWorld Science Financings Newco news Cancer Antibody-drug conjugate Seed U.S.
Synthetic Design emerges with $20M and next-gen ADC platform

3 weeks ago | bioworld.com | Jennifer Boggs

Newco newsSynthetic Design emerges with $20M and next-gen ADC platformSynthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders identifying a single clear goal: how to deliver more payload to a target cancer cell. BioWorld Financings Newco news Cancer Seed U.S.
Pfizer’s loss offers boost to competitors in obesity space

1 month ago | bioworld.com | Jennifer Boggs

Pfizer’s loss offers boost to competitors in obesity spacePfizer Inc. is ending work on oral GLP-1 candidate danuglipron for weight loss following the report of a single potentially drug-induced liver injury, a move that appears to open the door for other firms working on oral therapies in the high-dollar obesity space, even as industry watchers seek further details to determine whether similar safety signals could emerge for those competitors.
CMS rule ditches plan for Medicare coverage of obesity drugs

1 month ago | bioworld.com | Jennifer Boggs

CMS rule ditches plan for Medicare coverage of obesity drugsA late 2024 CMS proposal to include obesity drugs like Novo Nordisk A/S’ Wegovy (semaglutide) and Eli Lilly and Co.’s Zepbound (tirzepatide) under Medicaid and Medicare didn’t make it far under the new U.S. administration. A final rule, set to be published in the Federal Register April 15, will not include the provision that would have added obesity drugs to Part D coverage beginning in 2026. BioWorld Regulatory Obesity U.S. CMS Medicare
Another rebound as Sangamo inks $1.4B capsid deal with Lilly

1 month ago | bioworld.com | Jennifer Boggs

Another rebound as Sangamo inks $1.4B capsid deal with LillySangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly gets access to Sangamo’s neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has shown early promise in penetrating the blood-brain barrier penetration, for one initial target with the right to add up to four more.
Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia

1 month ago | bioworld.com | Jennifer Boggs

Sanofi adds to hemophilia arsenal with FDA nod for QfitliaSanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment to prevent or reduce bleeding episodes in people with hemophilia A or B, with or without inhibitors. BioWorld MedTech Regulatory Hematologic RNAi U.S. FDA
Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia

1 month ago | bioworld.com | Jennifer Boggs

Sanofi adds to hemophilia arsenal with FDA nod for QfitliaSanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment to prevent or reduce bleeding episodes in people with hemophilia A or B, with or without inhibitors, and joins the small but growing group of non-factor therapy options, with the advantage of a broad label and a convenient dosing regimen.